The FDA met today to discuss the COVID booster shot from Pfizer and they just voted against it by an overwhelming majority:
BREAKING: FDA panel votes against approving a Pfizer booster dose for COVID-19, weeks after President Joe Biden promised all Americans would be able to get boosters beginning in late September.
— Dylan Housman (@Dylan_Housman) September 17, 2021
WASHINGTON (AP) — FDA advisory panel soundly rejects a plan to offer Pfizer booster shots against COVID-19 to most Americans.
— Zeke Miller (@ZekeJMiller) September 17, 2021
FDA PANEL VOTES 16-3 AGAINST APPROVING COVID BOOSTER
— zerohedge (@zerohedge) September 17, 2021
Here’s more from Fox News:
An advisory panel for the U.S. Food and Drug Administration on Friday voted to reject a plan to offer booster dose of Pfizer-BioNTech’s COVID-19 vaccine for Americans, saying more data is needed to determine if boosters are safe and effective at this time.
The U.S. has already approved an extra dose of both the Pfizer or Moderna vaccines to people who are immunocompromised, or those with severely weakened immune systems.
A U.S. Food and Drug Administration (FDA) advisory panel on Friday declined to endorse the Pfizer-BioNTech COVID-19 vaccine booster shot for people ages 16 years and older at least six months following the second dose.
The vote was 2-16. The vote will now go before the FDA to issue a final decision.
During the deliberations, panel members suggested older, vulnerable populations may benefit from boosters, but noted insufficient data among younger groups and concerns over potential increased risk for heart inflammation, particularly among males ages 16-17.
The committee was charged with voting whether the safety and effectiveness data from Pfizer’s clinical trial supported approval of the company’s booster dose among people 16 years and older.
The meeting included members of the FDA’s Vaccines and Related Biological Products Advisory Committee, (VRBPAC), as well as officials from the Centers for Disease Control and Prevention (CDC), lsrael’s Health Ministry, vaccine experts and Pfizer representatives.
Dr. William Gruber, senior vice president of vaccine clinical research and development at Pfizer, noted Phase 3 trial data indicating waning protection over time, from 96% vaccine efficacy within two months after the second dose to about 84% by six months and amid the dominant delta variant. While protection dropped against infections, it remained effective in preventing hospitalizations.
Gruber cited evidence suggesting reductions in efficacy owed to waning immunity over time as opposed to the delta variant escaping vaccine protection. Additional data suggested a third Pfizer dose would ramp up protection on par or better than the second dose, however concerns were raised over a potential increased risk of heart inflammation among some recipients, particularly among males ages 16-17. The FDA panel’s review included Pfizer’s trial results with some 300 participants ages 18-55 who received a booster dose about six months after the second dose.
To be clear, the role of the FDA and advisory panel in this case is to determine whether an additional dose can be used, whereas an expert panel advising the CDC (Advisory Committee on Immunization Practices, ACIP), will convene Wednesday to weigh a recommendation on shots, following FDA review. Top health officials last month said this group would likely include health care workers and nursing home residents who were targeted in the earliest phases of the rollout.
You’d think that if this Pfizer booster has any chance of coming to an arm near you, it wouldn’t have gotten this kind of rejection by the FDA advisory board. I think it at this point it will be shocking if the FDA itself approves the vaccine at this point.
The post BREAKING: Biden promised COVID booster shots but the FDA panel just overwhelmingly REJECTED IT appeared first on News Thud.
Click this link for the original source of this article.
Author: J.C McCallum
This content is courtesy of, and owned and copyrighted by, https://newsthud.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.